In-vitro tools to simulate chewing of pharmaceutical opioid drug products
Ended Definitive Contract Awarded Last action
- Contract number
- 75F40121C00178
- Awardee
-
The University Of Auckland UEI F1EHWJFBEWL8
- Awarding agency
-
Food and Drug Administration
Department of Health and Human Services
- Obligated
- $554,827
Award facts
- Contract value 100% obligated
- $554,827.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 611310 Colleges, Universities, and Professional Schools
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 3 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Silver Spring, MD 20993, USA
- Legislative mandates
-
- Service Contract Act FAR subpart 22.10
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Additional Work (new agreement, FAR part 6 applies) | $209,712 | |
| Other Administrative Action | $0 | |
| Original award | $345,115 |
About this award
The Food and Drug Administration awarded a $554.8K definitive contract on September 16, 2021, to The University of Auckland Research Office to develop in-vitro tools designed to simulate the chewing of pharmaceutical opioid drug products. This firm fixed-price contract, which carries an ultimate completion date of March 31, 2025, supports FDA's regulatory science mission by advancing methodologies that evaluate how opioid medications behave under physiological conditions relevant to human consumption. The work will be performed at the FDA's facility in Silver Spring, Maryland. No set-aside designation was used in this competitive award.
The University of Auckland, a prominent international research institution based in Auckland, New Zealand, maintains substantial federal contracting experience with U.S. agencies including the FDA and NASA. The university's Research Office Division brings established capabilities in biomedical sciences and pharmaceutical product characterization, with prior contract work focused on developing innovative in-vitro testing methodologies for drug product evaluation. This contract aligns with the FDA's broader efforts to enhance regulatory science tools and methodologies that support pharmaceutical safety and efficacy assessment, particularly for controlled substances subject to heightened regulatory scrutiny.
Quick answers
Who was awarded contract 75F40121C00178?
75F40121C00178 was awarded to The University Of Auckland by Food and Drug Administration (Department of Health and Human Services) on September 16, 2021.
How much is contract 75F40121C00178 worth?
The government has obligated $554,827 on 75F40121C00178.
Was contract 75F40121C00178 competed?
The extent of competition for 75F40121C00178 was full and open competition. The government received 3 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award